PROVEN EFFICACY
The first FDA‑approved CLS proven to reduce the incidence of CRBSIs by 71%1
Studied in the largest trial to date in the US in patients receiving hemodialysis via CVC. DefenCath has proven to help reduce CRBSIs.1,2
HOW DEFENCATH WORKS
A first-in-class CLS with taurolidine + heparin1
DefenCath is the only FDA-approved solution that protects the CVC lumen pathway with antimicrobial activity.1
Explore MOA
SAFETY
Trust in a demonstrated
safety profile
In a pivotal clinical study, DefenCath was shown to have a similar safety profile as standard‑of‑care (SOC) heparin, and risk of adverse events were similar1,3
USING DEFENCATH
Can be utilized with commonly used HD-CVCs
DefenCath, with refrigeration-free storage, can be utilized with commonly used HD-CVCs and is administered similarly to standard-of-care (heparin).1,3
DEFENCATH RESOURCE PORTAL
Get information and helpful downloads about
DefenCath®
(taurolidine and heparin)
catheter lock solution
Discover resources and tools for protocol adoption, implementation best practices, ordering information, reimbursement, and more.
Speak with a representative
Have questions about DefenCath? Open the form below to request a call with a representative.
IMPORTANT SAFETY INFORMATION (cont'd)
CONTRAINDICATIONS
DefenCath is contraindicated in patients with:
- Known heparin-induced thrombocytopenia (HIT).
- Known hypersensitivity to taurolidine, heparin or the citrate excipient (components of DefenCath), or pork products.
WARNINGS AND PRECAUTIONS
- Heparin-Induced Thrombocytopenia (HIT): HIT was reported in patients using heparin, a component of DefenCath, as a catheter lock solution. If HIT occurs, discontinue DefenCath and institute appropriate supportive measures.
- Drug Hypersensitivity: Drug hypersensitivity reactions have been reported in patients using heparin, a component of DefenCath, as a catheter lock solution. If a hypersensitivity reaction occurs, discontinue DefenCath and institute appropriate supportive measures.
ADVERSE REACTIONS
The most frequently reported adverse reactions occurring in ≥2% of patients using DefenCath as a CLS were hemodialysis catheter malfunction, hemorrhage/bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia.
Indications and Usage
LIMITED POPULATION: DefenCath® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.
Limitations of Use
The safety and effectiveness of DefenCath have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.
Please see the full Prescribing Information.